GSK has agreed to acquire Boston-based biotech firm Nuvalent for $10.6 billion in cash, paying $124 per share, a 40% premium over the last closing price. This marks GSK's largest acquisition in over a decade and aims to strengthen its lung cancer drug pipeline with Nuvalent's lead candidates, including zidesamtinib and neladalkib. The deal is expected to drive revenue growth and improve profits starting in 2027, with core earnings per share rising from 2029. The acquisition comes amid a competitive biotech landscape focused on cancer therapies and patent expirations.
British pharmaceutical company GSK announced it will acquire cancer drug developer Nuvalent for $10.6 billion. This deal caused Nuvalent's stock to surge 39% as investors reacted positively to the acquisition. The move highlights GSK's strategic inve...
GSK has agreed to acquire U.S. biotech company Nuvalent for $10.6 billion, marking its largest purchase in eight years. This move aims to strengthen GSK's cancer drug offerings, which it had previously reduced. The deal follows GSK's 2018 acquisition...
GSK has agreed to acquire US biotech firm Nuvalent for $10.6 billion (£8 billion) to enhance its oncology portfolio with advanced lung cancer treatments and other assets. The deal includes late-stage drugs zidesamtinib and neladalkib, both under FDA ...
UK pharmaceutical company GSK is negotiating to acquire oncology biotech Nuvalent for more than $9 billion, potentially finalizing the deal this week. This acquisition would be GSK's largest in over ten years and marks a shift from its recent smaller...
Engitix Ltd. has entered a strategic collaboration with GSK to identify and validate new therapeutic targets aimed at reversing liver fibrosis. The partnership leverages Engitix’s human extracellular matrix (ECM) platform and multi-omics data alongsi...
